Equibles does not estimate personal net worth.
Get an email with a short summary when Generate Biomedicines, Inc. publishes a filing, an earnings call transcript or a press release.
Get GENB alertsJason Silver is recorded as CFO at Generate Biomedicines, Inc. (GENB). Jason Silver has spoken on 3 investor events across 1 company, most recently for Generate Biomedicines, Inc. on September 16, 2026. Generate Biomedicines, Inc. is classified in the Biotechnology industry within the Healthcare sector.
“So T-slip is a known mechanism in asthma. The test buyer has been on the market for five years. It's a biologic. Biologics in respiratory and asthma particularly are very low penetrated.”
“Yeah, so efficacy is probably not the direction that we'll take this, although in preclinical studies we did show kind of a five-time improvement in potency over Testfire.”
“I would just add a few things that are differentiating, I think, for us. Number one, we're large molecule only. Two, we're modality agnostic. So this is not just an antibody company.”
Biotechnology · Healthcare
CFO
